Lee's Pharmaceutical Holdings (HKSE:00950) Debt-to-Equity : 0.14 (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Debt-to-Equity?

Lee's Pharmaceutical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$169 Mil. Lee's Pharmaceutical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$78 Mil. Lee's Pharmaceutical Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$1,714 Mil. Lee's Pharmaceutical Holdings's debt to equity for the quarter that ended in Jun. 2024 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lee's Pharmaceutical Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:00950' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.14
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of Lee's Pharmaceutical Holdings was 0.14. The lowest was 0.04. And the median was 0.07.

HKSE:00950's Debt-to-Equity is ranked better than
65.86% of 829 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs HKSE:00950: 0.14

Lee's Pharmaceutical Holdings Debt-to-Equity Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Debt-to-Equity Chart

Lee's Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.11

0.09

0.10

Lee's Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.11	0.09	0.10	0.10	0.14

Competitive Comparison of Lee's Pharmaceutical Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lee's Pharmaceutical Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Debt-to-Equity falls into.

Lee's Pharmaceutical Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lee's Pharmaceutical Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(129.571	+	74.569)	/	2038.955
	=	0.10

Lee's Pharmaceutical Holdings's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(168.919	+	78.492)	/	1713.545
	=	0.14

Lee's Pharmaceutical Holdings (HKSE:00950) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lee's Pharmaceutical Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Debt-to-Equity

Traded in Other Exchanges

LPCUF:USA L1PA:Germany

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Executives

Leelalertsuphakun Wanee	2101 Beneficial owner
Huang Zuie-chin	2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky	2202 Interest of your spouse
Li Xiaoyi	2101 Beneficial owner
Lee Siu Fong	2101 Beneficial owner
Ubs Group Ag	2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p.	2101 Beneficial owner
Panacea Innovation Limited	2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Qualister Sa	2101 Beneficial owner
Paponi Claudia	2202 Interest of your spouse
Cavazza Paolo	2201 Interest of corporation controlled by you
Apta Finance Sa	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Gsr Capital Joy Corporation	2101 Beneficial owner

Lee's Pharmaceutical Holdings Headlines

No Headlines